CN112313207A - 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 - Google Patents

一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 Download PDF

Info

Publication number
CN112313207A
CN112313207A CN201980038142.8A CN201980038142A CN112313207A CN 112313207 A CN112313207 A CN 112313207A CN 201980038142 A CN201980038142 A CN 201980038142A CN 112313207 A CN112313207 A CN 112313207A
Authority
CN
China
Prior art keywords
substituted
amino
alkyl
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980038142.8A
Other languages
English (en)
Other versions
CN112313207B (zh
Inventor
张强
于善楠
孙月明
刘彦生
李兴福
郑南桥
杨磊夫
胡晨明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Scitech MQ Pharmaceuticals Ltd
Original Assignee
Beijing Scitech MQ Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Scitech MQ Pharmaceuticals Ltd filed Critical Beijing Scitech MQ Pharmaceuticals Ltd
Publication of CN112313207A publication Critical patent/CN112313207A/zh
Application granted granted Critical
Publication of CN112313207B publication Critical patent/CN112313207B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

提供一种式(I)所示化合物、其异构体、水合物、溶剂化物、其药学上可接受的盐及其前药，其制备方法及其在制备作为激酶抑制剂的药物中的应用。该化合物对FGFR4及突变型FGFR4V550L等激酶均具有良好的抑制活性。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201980038142.8A 2018-06-22 2019-06-20 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 Active CN112313207B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810651996 2018-06-22
CN2018106519960 2018-06-22
PCT/CN2019/092089 WO2019242689A1 (zh) 2018-06-22 2019-06-20 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用

Publications (2)

Publication Number Publication Date
CN112313207A true CN112313207A (zh) 2021-02-02
CN112313207B CN112313207B (zh) 2023-02-14

Family

ID=68983446

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980038142.8A Active CN112313207B (zh) 2018-06-22 2019-06-20 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用

Country Status (2)

Country Link
CN (1) CN112313207B (zh)
WO (1) WO2019242689A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220114643A (ko) * 2019-12-23 2022-08-17 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 시아노-치환된 피리딘 및 시아노-치환된 피리미딘 화합물 및 이의 제조방법 및 이의 적용
CN113754591B (zh) * 2020-06-05 2024-01-05 山东大学 一种hdac、jak和bet三靶点抑制剂及其制备方法和应用
CN114560815A (zh) * 2022-03-04 2022-05-31 北京工业大学 (2-((5-氯-取代苯基氨基嘧啶-2-基)氨基)苯基)氨基甲酸叔丁酯类衍生物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057963A1 (en) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Fgfr4 inhibitors
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
WO2017202390A1 (zh) * 2016-05-27 2017-11-30 杭州英创医药科技有限公司 作为fgfr4抑制剂的杂环化合物
WO2018072707A1 (zh) * 2016-10-18 2018-04-26 保诺科技（北京）有限公司 芳香族醚类衍生物、其制备方法及其在医药上的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2872491T3 (da) * 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057963A1 (en) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Fgfr4 inhibitors
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
WO2017202390A1 (zh) * 2016-05-27 2017-11-30 杭州英创医药科技有限公司 作为fgfr4抑制剂的杂环化合物
WO2018072707A1 (zh) * 2016-10-18 2018-04-26 保诺科技（北京）有限公司 芳香族醚类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2019242689A1 (zh) 2019-12-26
CN112313207B (zh) 2023-02-14

Similar Documents

Publication Publication Date Title
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
AU2019211491B2 (en) 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof
WO2015127872A1 (zh) 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
WO2016026445A1 (zh) 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
CN103003262A (zh) 含氮芳香族杂环衍生物
CA2944959C (en) Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
CN105384694B (zh) 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
WO2018010514A1 (zh) 作为fgfr抑制剂的杂环化合物
WO2014090692A1 (en) Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
CA2999379A1 (en) 2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
WO2020215998A1 (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
JP2024502178A (ja) Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体
CN113087671B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
KR102130253B1 (ko) 신규한 티아졸 유도체 및 이의 약학적으로 허용가능한 염
WO2022253081A1 (zh) 氧化膦衍生物及其制备方法和应用
CA3054753A1 (en) Pyridyl derivatives as bromodomain inhibitors
TWI819470B (zh) Fgfr激酶抑制劑及其應用
WO2020200154A1 (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
WO2021168521A1 (en) Inhibitors of necroptosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant